R Squared LTD Editas Medicine, Inc. Transaction History

R Squared LTD

$181 Billion
Q2 2025

A detailed history of R Squared LTD transactions in Editas Medicine, Inc. stock. As of the latest transaction made, R Squared LTD holds 20,625 shares of EDIT stock, worth $80,850. This represents 0.03% of its overall portfolio holdings.

Number of Shares

20,625

Holding current value

$80,850

% of portfolio

0.03%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2025 Jul 31, 2025	BUY	$0.98 - $2.35 $20,212 - $48,468	20,625 New	20,625 $45.4 Million
Q4 2024 Jan 22, 2025	BUY	$1.2 - $3.76 $3,288 - $10,302	2,740 New	2,740 $3.48 Million

Others Institutions Holding EDIT

# of Institutions

218

Shares Held

45.5M

Call Options Held

476K

Put Options Held

338K

Black Rock Inc. New York, NY

7.78M
Shares

$30.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

7.16M
Shares

$28.1 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.96M
Shares

$7.7 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.88M
Shares

$7.36 Million
0.0% of portfolio
State Street Corp Boston, MA

1.85M
Shares

$7.24 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $269M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.

Account